Industry
Biotechnology
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Loading...
Open
9.20
Mkt cap
569M
Volume
577K
High
9.33
P/E Ratio
-6.91
52-wk high
13.68
Low
8.80
Div yield
N/A
52-wk low
2.18
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 12:06 pm
Portfolio Pulse from Avi Kapoor
September 05, 2024 | 5:44 pm
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 9:42 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:16 am
Portfolio Pulse from Avi Kapoor
June 26, 2024 | 11:36 am
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 11:41 am
Portfolio Pulse from Avi Kapoor
May 31, 2024 | 5:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 3:46 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.